Toll Free: 1-888-928-9744

Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 141 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016', provides an overview of the Dry (Atrophic) Macular Degeneration pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration
- The report reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Dry (Atrophic) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Dry (Atrophic) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Dry (Atrophic) Macular Degeneration Overview 11 Therapeutics Development 12 Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview 12 Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis 13 Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies 14 Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 16 Dry (Atrophic) Macular Degeneration - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Dry (Atrophic) Macular Degeneration - Products under Development by Companies 21 Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes 23 Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development 24 Aciont Inc. 24 Acucela Inc. 25 Alimera Sciences, Inc. 26 Allergan Plc 27 Apellis Pharmaceuticals, Inc. 28 Astellas Pharma Inc. 29 Benitec Biopharma Limited 30 Biophytis SAS 31 Catalyst Biosciences, Inc. 32 Cell Cure Neurosciences, Ltd. 33 Foamix Pharmaceuticals Ltd. 34 Genentech, Inc. 35 GenSight Biologics S.A. 36 GlaxoSmithKline Plc 37 Icon Bioscience, Inc. 38 Johnson & Johnson 39 Kodiak Sciences, Inc. 40 MacuCLEAR, Inc. 41 Novartis AG 42 Ophthotech Corp. 43 Orphagen Pharmaceuticals, Inc. 44 pSivida Corp. 45 Sucampo Pharmaceuticals, Inc. 46 Sun Pharma Advanced Research Company Ltd. 47 Dry (Atrophic) Macular Degeneration - Therapeutics Assessment 48 Assessment by Monotherapy Products 48 Assessment by Target 49 Assessment by Mechanism of Action 51 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 APL-2 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 avacincaptad pegol sodium - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 BIO-201 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 BIO-203 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 brimonidine tartrate implant - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 CLG-561 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 CNTO-2476 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Drug for Age Related Macular Degeneration - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Drug for Wet AMD and Dry AMD - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 EG-30 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 emixustat hydrochloride - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 fluocinolone acetonide SR - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 FMX-103 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Gene Therapy for Ocular Diseases - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 GS-030 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 GSK-933776 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 ICR-14967 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 KSI-401 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 lampalizumab - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 MA09-hRPE - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 MC-1101 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 methotrexate - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 OCU-100 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 ONL-1204 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 OpRegen - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 OpRegen Plus - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 RC-1 Alpha - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 RST-001 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Small Molecules for AMD - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Small Molecules for Dry Age-Related Macular Degeneration - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 tesidolumab - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 TT-231 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 unoprostone isopropyl - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 VM-100 - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 Dry (Atrophic) Macular Degeneration - Recent Pipeline Updates 107 Dry (Atrophic) Macular Degeneration - Dormant Projects 130 Dry (Atrophic) Macular Degeneration - Discontinued Products 132 Dry (Atrophic) Macular Degeneration - Product Development Milestones 133 Featured News & Press Releases 133 May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences 133 Nov 17, 2015: Biophytis establishes New subsidiary to accelerate clinical development of Maculia 133 Sep 28, 2015: Alimera Sciences Announces Availability Of Review Paper On Real World Experience With ILUVIEN 133 Oct 18, 2013: Alimera Sciences Receives Complete Response Letter For ILUVIEN 134 Oct 01, 2013: Roche to present data on Lampalizumab at investor event 135 Aug 27, 2013: Roche's lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration 136 Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials 137 May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells 138 Apr 15, 2013: ACT Treats First Patient With Better Vision In Clinical Trial For Stargardt's Macular Dystrophy 138 Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy 139 Appendix 140 Methodology 140 Coverage 140 Secondary Research 140 Primary Research 140 Expert Panel Validation 140 Contact Us 140 Disclaimer 141
List of Tables
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H1 2016 12 Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Comparative Analysis by Unknown Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Dry (Atrophic) Macular Degeneration - Pipeline by Aciont Inc., H1 2016 24 Dry (Atrophic) Macular Degeneration - Pipeline by Acucela Inc., H1 2016 25 Dry (Atrophic) Macular Degeneration - Pipeline by Alimera Sciences, Inc., H1 2016 26 Dry (Atrophic) Macular Degeneration - Pipeline by Allergan Plc, H1 2016 27 Dry (Atrophic) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H1 2016 28 Dry (Atrophic) Macular Degeneration - Pipeline by Astellas Pharma Inc., H1 2016 29 Dry (Atrophic) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H1 2016 30 Dry (Atrophic) Macular Degeneration - Pipeline by Biophytis SAS, H1 2016 31 Dry (Atrophic) Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H1 2016 32 Dry (Atrophic) Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H1 2016 33 Dry (Atrophic) Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 34 Dry (Atrophic) Macular Degeneration - Pipeline by Genentech, Inc., H1 2016 35 Dry (Atrophic) Macular Degeneration - Pipeline by GenSight Biologics S.A., H1 2016 36 Dry (Atrophic) Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H1 2016 37 Dry (Atrophic) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H1 2016 38 Dry (Atrophic) Macular Degeneration - Pipeline by Johnson & Johnson, H1 2016 39 Dry (Atrophic) Macular Degeneration - Pipeline by Kodiak Sciences, Inc., H1 2016 40 Dry (Atrophic) Macular Degeneration - Pipeline by MacuCLEAR, Inc., H1 2016 41 Dry (Atrophic) Macular Degeneration - Pipeline by Novartis AG, H1 2016 42 Dry (Atrophic) Macular Degeneration - Pipeline by Ophthotech Corp., H1 2016 43 Dry (Atrophic) Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016 44 Dry (Atrophic) Macular Degeneration - Pipeline by pSivida Corp., H1 2016 45 Dry (Atrophic) Macular Degeneration - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 46 Dry (Atrophic) Macular Degeneration - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 47 Assessment by Monotherapy Products, H1 2016 48 Number of Products by Stage and Target, H1 2016 50 Number of Products by Stage and Mechanism of Action, H1 2016 52 Number of Products by Stage and Route of Administration, H1 2016 54 Number of Products by Stage and Molecule Type, H1 2016 56 Dry (Atrophic) Macular Degeneration Therapeutics - Recent Pipeline Updates, H1 2016 107 Dry (Atrophic) Macular Degeneration - Dormant Projects, H1 2016 130 Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..1), H1 2016 131 Dry (Atrophic) Macular Degeneration - Discontinued Products, H1 2016 132


List of Figures
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H1 2016 12 Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Products, H1 2016 19 Assessment by Monotherapy Products, H1 2016 48 Number of Products by Top 10 Targets, H1 2016 49 Number of Products by Stage and Top 10 Targets, H1 2016 49 Number of Products by Top 10 Mechanism of Actions, H1 2016 51 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 51 Number of Products by Routes of Administration, H1 2016 53 Number of Products by Stage and Routes of Administration, H1 2016 53 Number of Products by Top 10 Molecule Types, H1 2016 55 Number of Products by Stage and Top 10 Molecule Types, H1 2016 55

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify